论文部分内容阅读
目的:探讨黄芪联合低分子肝素治疗儿童原发性肾病综合症的疗效。方法:收集近几年我院原发性肾病综合症的患儿,疾病符合2001年全国儿童科肾脏病制定的标准。随机分为:研究组和对照组,两组基础治疗方案相同,研究组加用黄芪联合低分子肝素治疗。对比1两组治疗前后24h尿蛋白、尿素氮、肌酐。2两组原发性肾病综合症治疗疗效。结果:1两组治疗前24h尿蛋白、尿素氮、肌酐比较无差异(P>0.05);两组治疗后24h尿蛋白、尿素氮、肌酐比较有差异(P<0.05)。2两组原发性肾病综合症治疗疗效分别为70%、50%,比较有差异(P<0.05)。论:黄芪联合低分子肝素治疗儿童原发性肾病综合症疗效肯定,能明显改善患者水肿、低蛋白等症状。
Objective: To investigate the curative effect of astragalus combined with low molecular weight heparin on children with primary nephrotic syndrome. Methods: Collecting children with primary nephrotic syndrome in our hospital in recent years, the disease is in line with the 2001 national pediatric kidney disease standards. Randomly divided into: the study group and the control group, two groups of the same basic treatment programs, the study group plus astragalus combined with low molecular weight heparin treatment. Comparison of two groups before and after treatment 24h urinary protein, urea nitrogen, creatinine. 2 two primary nephrotic syndrome curative effect. Results: There was no difference in urinary protein, urea nitrogen and creatinine between the two groups before treatment (P> 0.05). There was significant difference of urinary protein, urea nitrogen and creatinine between the two groups before treatment (P <0.05). The therapeutic effect of the two primary nephrotic syndromes was 70% and 50%, respectively (P <0.05). On: Astragalus combined with low molecular weight heparin treatment of children with primary nephrotic syndrome positive effect, can significantly improve the patient’s edema, low protein and other symptoms.